 This Phase 3, multicenter, open-label study will assess the long-term safety and tolerability of continuous subcutaneous infusion of apomorphine in advanced Parkinsons disease PD patients whose motor fluctuations remain unsatisfactory with levodopa or levodopacarbidopa and at least one other class of drugs or mode of therapy for PD. 